Halozyme Therapeutics, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Helen I. Torley
- Full Time Employees
- 423
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- 12390 El Camino Real San Diego CA United States 92130
- IPO Date
- Jan 30, 2003
- CIK
- 0001159036
- Website
- halozyme.com
- Similar Companies
- Business
- Halozyme Therapeutics, Inc. (NASDAQ: HALO) is a biopharmaceutical company that develops and commercializes proprietary enzyme-based drug delivery technologies and oncology therapies. The company's core ENHANZE platform, powered by the patented recombinant human hyaluronidase enzyme (rHuPH20), facilitates subcutaneous delivery of injectable biologics including monoclonal antibodies, other therapeutic molecules, small molecules, and fluids; it supports partnered products such as DARZALEX FASPRO (subcutaneous), Phesgo, VYVGART Hytrulo, Tecentriq Subcutaneous, and Ocrevus Subcutaneous across oncology, immunology, and neurology indications. Halozyme also commercializes XYosted, a testosterone replacement therapy via an auto-injector, and previously marketed Hylenex and Tlando prior to license terminations. Founded in 1998 and headquartered in San Diego, California, Halozyme operates primarily in the United States with global partnerships enabling international reach through collaborators in pharmaceutical and biotechnology sectors targeting diabetes, cancer, dermatology, autoimmune diseases, and rare disorders. In recent developments, Halozyme completed the acquisition of Elektrofi in late 2025 for up to $900 million, integrating the Hypercon microparticle technology to expand subcutaneous delivery options and strengthen partnerships with big pharma; the deal includes $750 million upfront plus milestones tied to product approvals, with royalties expected from 2030. The company expanded its argenx collaboration with an upfront payment and milestones, secured a new global agreement with Merus N.V. for ENHANZE in bispecific antibodies, and gained regulatory approvals for Roche's Tecentriq and Ocrevus subcutaneous formulations; partners nominated five new targets for clinical advancement in 2024, contributing to record 2024 revenue exceeding $1 billion. These initiatives underscore Halozyme's focus on organic pipeline growth, strategic alliances, and share repurchases up to $250 million.
Company News
Halozyme Stock Down Despite Q3 Earnings and Revenue Beat
HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute
Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer
What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Call
Compared to Estimates, Halozyme Therapeutics (HALO) Q3 Earnings: A Look at Key Metrics
Halozyme Therapeutics (HALO) Tops Q3 Earnings and Revenue Estimates
HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
Halozyme Therapeutics (HALO) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth
HALO-Flight Strengthens its Texas-based Air Med Fleet with Additional Bell 407GXi Purchase Order
Which Healthcare ETF Is the Better Buy: Invesco’s Broad RSPH or First Trust’s Biotech FBT?
11,095 Halozyme Therapeutics, Inc. $HALO Shares Purchased by Gibbs Wealth Management
Halozyme to Report Third Quarter 2026 Financial and Operating Results
5 Strong Buy Growth Stocks With High Margins to Grab Before Earnings
Halozyme's Strong Earnings Growth Sends Shares Higher
Halozyme Therapeutics, Inc. $HALO Stock Position Cut by First Citizens Bank & Trust Co.
5 Stocks to Buy Using the Relative Price Strength Strategy